| Target Molecule | ACTH (1-24) |
| Synonyms | Tetracosactide, Cosyntropin, Tetracosactrin, Synacthen, Cortrosyn |
| CAS Number | 16960-16-0 |
| Sequence (3-Letter) | H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH |
| Sequence (1-Letter) | SYSMEHFRWGKPVGKKRRPVKVYP |
| Molecular Formula | C₁₃₆H₂₁₀N₄₀O₃₁S |
| Molecular Weight | 2933.4 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical salt), TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) for Basic Mid-Length Sequences |
| Modification Options | Stable isotope labeling (13C, 15N), fluorescent tagging, fragment cascade synthesis (ACTH 1-10, ACTH 1-39), Met-oxidation standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and extended regulatory documentation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
ACTH (1-24) (CAS 16960-16-0), also known as tetracosactide or cosyntropin, is a 24-amino acid peptide (SYSMEHFRWGKPVGKKRRPVKVYP) corresponding to the biologically active N-terminal domain of full-length adrenocorticotropic hormone. We target this sequence to supply high-purity reference materials and raw materials for endocrine and diagnostic research.
Synthesizing a 24-residue peptide containing an intensive basic cluster (Lys-Lys-Arg-Arg) and sensitive residues (Met4, Trp9) carries severe risks of incomplete coupling and oxidative degradation. Our peptide synthesis platform utilizes optimized solid-phase peptide synthesis (SPPS) protocols, high-efficiency coupling reagents, and inert gas handling during cleavage to suppress side reactions and deliver superior purity.
Yes. We provide extensive peptide modification services for ACTH analogues. Capabilities include site-specific stable isotope labeling (13C, 15N) for quantitative mass spectrometry (LC-MS/MS), fluorescent and biotin labeling, and the synthesis of established active fragments such as ACTH (1-10) and full-length ACTH (1-39) as comparative reference standards.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (such as TFA removal to acetate) to ensure strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, impurity profiling, analytical method validation, and regulatory documentation to advance complex preclinical and commercial pipelines.
ACTH (1-24) (CAS 16960-16-0), commonly known as tetracosactide or cosyntropin, is a synthetic 24-residue peptide reproducing the full steroidogenic activity of natural adrenocorticotropic hormone. Synpeptide provides comprehensive custom synthesis solutions for this molecule. Constructing a 24-amino acid sequence with an enriched basic core and sensitive oxidation sites demonstrates our technical expertise in mid-length solid-phase assembly, impurity suppression, and CDMO manufacturing.
Assembling a 24-residue sequence containing consecutive basic residues (Lys15-Lys16-Arg17-Arg18) presents severe challenges regarding on-resin aggregation and steric hindrance. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols on low-loading resins. By implementing high-efficiency coupling reagents, precise temperature control, and inert gas handling to protect Met4 and Trp9, we suppress deletion fragments and deliver raw materials with rigorous purity specifications (typically ≥95% or ≥98% via HPLC).
Endocrine pharmacology and pharmacokinetic assays require tailored peptide derivatives. Through our peptide modification services, we routinely synthesize related cascade fragments, including ACTH (1-10) and full-length ACTH (1-39). We also incorporate heavy stable isotopes (13C, 15N) for quantitative mass spectrometry, attach fluorescent labels for receptor localization assays, and synthesize methionine sulfoxide variants as stability-indicating impurity reference standards.
Transitioning a 24-residue peptide from exploratory laboratory scale to commercial supply demands robust chemical engineering during downstream processing. The basic character of the sequence requires tailored chromatographic isolation. We execute large-scale peptide synthesis for ACTH (1-24) by optimizing fluid dynamics and high-capacity preparative HPLC purification. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (providing the pharmaceutical acetate salt form) across all production volumes.
We deliver comprehensive technical support as a fully integrated peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete analytical documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream therapeutic programs.
